{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:33:41Z","timestamp":1790066021379,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004316","name":"International Business Machines Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ygyno.2018.09.003","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T04:33:40Z","timestamp":1538022820000},"page":"190-195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States"],"prefix":"10.1016","volume":"151","author":[{"given":"Rahul","family":"Shenolikar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Durden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Lenhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.09.003_bb0005","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.seminoncol.2008.04.012","article-title":"Therapy-related myeloid leukemia","volume":"35","author":"Godley","year":"2008","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2018.09.003_bb0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejcsup.2014.05.001","article-title":"Current knowledge and future research directions in treatment-related second primacy malignancies","volume":"12","author":"Morton","year":"2014","journal-title":"EJC Suppl."},{"key":"10.1016\/j.ygyno.2018.09.003_bb0015","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.09.003_bb0020","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/sj.leu.2403947","article-title":"Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients","volume":"19","author":"Rund","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.ygyno.2018.09.003_bb0025","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1182\/blood-2012-08-448068","article-title":"Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975\u20132008","volume":"121","author":"Morton","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ygyno.2018.09.003_bb0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdn530","article-title":"Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers","volume":"20","author":"Beadle","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2018.09.003_bb0035","series-title":"New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973\u20132000","article-title":"Chapter 7, new malignancies following breast cancer","author":"Curtis","year":"2006"},{"key":"10.1016\/j.ygyno.2018.09.003_bb0040","series-title":"New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973\u20132000","article-title":"Chapter 9, new malignancies following cancer of the uterine corpus and ovary","author":"Freedman","year":"2006"},{"key":"10.1016\/j.ygyno.2018.09.003_bb0045","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/jnci\/86.17.1315","article-title":"Relationship of leukemia risk to radiation dose following cancer of the uterine corpus","volume":"86","author":"Curtis","year":"1994","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2018.09.003_bb0050","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/cncr.25067","article-title":"Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma","volume":"116","author":"Wright","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2018.09.003_bb0055","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-015-3590-1","article-title":"Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer","volume":"154","author":"Calip","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2018.09.003_bb0060","unstructured":"E. Pujade-Lauraine, J. Ledermann, R. Penson, et al., Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO2 study. Presented at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO), March 12\u201315. (National Harbor, Maryland)."},{"key":"10.1016\/j.ygyno.2018.09.003_bb0065","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2011-02-337964","article-title":"Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries","volume":"117","author":"Cogle","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2018.09.003_bb0070","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1158\/1055-9965.EPI-11-1087","article-title":"Underreporting of myeloid malignancies by United States cancer registries","volume":"21","author":"Craig","year":"2012","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2018.09.003_bb0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199902043400504","article-title":"Risk of leukemia after platinum-based chemotherapy for ovarian cancer","volume":"340","author":"Travis","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ygyno.2018.09.003_bb0080","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1200\/JCO.2007.12.0832","article-title":"Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk","volume":"25","author":"Patt","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2018.09.003_bb0085","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.breast.2005.11.007","article-title":"Increased risk of acute myeloid leukaemia after treatment for breast cancer","volume":"15","author":"Renella","year":"2006","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.ygyno.2018.09.003_bb0090","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1200\/JCO.2003.03.114","article-title":"Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience","volume":"21","author":"Smith","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.09.003_bb0095","first-page":"937","article-title":"The incidence of secondary leukemias","volume":"84","author":"Leone","year":"1999","journal-title":"Haematologica"},{"key":"10.1016\/j.ygyno.2018.09.003_bb0100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jnci\/88.7.407","article-title":"The secondary leukemias: challenges and research directions","volume":"88","author":"Smith","year":"1996","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818311764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818311764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:41:21Z","timestamp":1758771681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818311764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0090825818311764"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.09.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}